Resistance to saquinavir , an inhibitor of human immunodeficiency virus type 1 proteinase, was studied in peripheral blood mononuclear cell-derived proviral DNA from patients undergoing prolonged treatment. A Leu90-Met exchange was the predominant resistance mutation in vivo; Gly48-Val or doubly mutant virus was rarely observed. After 8-12 months of treatment with saquinavir alone (600 mg, 3 times/day) or in combination with zidovudine (200 mg, 3 times/ day),~45% of all patients carried provirus with mutant proteinase; the incidence was lower (22%) in patients treated with a combination of saquinavir, zidovudine, and dideoxycytidine. There was a good relationship between genotypic analysis of saquinavir resistance and data from virus assays, confirming that Leu90-Met and Gly48-Val are the essential exchanges in the proteinase that determine loss of sensitivity to this inhibitor. Absence of genotypic resistance correlated with a sustained decrease in plasma viral RNA. There was a positive correlation between a Met90 mutation and some residues at natural polymorphic sites (positions 10, 36, 63, and 71).
Replication of retrovirus and release of infectious progeny virus requires the processing of gag and gag-pol precursor proteins by virus-encoded aspartic proteinase [1, 2] . Inhibition of human immunodeficiency virus (HIV) type 1 proteinase either by mutational inactivation of its catalytic aspartic acid or by specific inhibitors leads to the accumulation of noninfectious, immature virus particles and impairs the spread of virus infection in cell culture [3] [4] [5] [6] . Thus, HIV-l proteinase has been recognized as a suitable target for antiviral therapy, and several effective and specific low-molecular-weight proteinase inhibitors have been described [7] [8] [9] [10] [11] . Saquinavir (Ro 31-8959) is such an inhibitor. It is highly active and selective against the aspartic proteinases of HIV-1 and -2 and of simian immunodeficiency virus and exerts its potent antiviral activity in cell culture at concentrations in the low nanomolar range [12, 13] . Extensive phase 1111 and III clinical studies have been completed or are ongoing [14] .
The emergence of virus variants with greatly decreased sensitivity to inhibitors of reverse transcriptase (RT) is common in the clinical application of this class of therapeutics [15] [16] [17] [18] [19] . A number of variant RT genes have been observed after drug exposure in cell culture and in vivo that are significantly less sensitive to inhibitor [20] [21] [22] [23] . Multidrug resistance has been observed after subsequent or concurrent exposure to different inhibitors. Significant decreases in susceptibility to proteinase inhibitors have also been observed after prolonged cultivation of virus in the presence of such agents, and specific mutations in the proteinase have been determined [24] [25] [26] [27] [28] . For saquinavir, HIV-1 variants have been selected with two predominant exchanges in the proteinase, Gly48-Val (G48V) and Leu90 -Met [L90M; [29] [30] [31] . When introduced into wild type proteinase by directed mutagenesis, each exchange leads to a moderate decrease in sensitivity (3-to lO-fold), whereas the simultaneous occurrence of both mutations causes a more severe loss in susceptibility (~IOO-fold) [30] . This study assessed if and to what extent genotypic resistance to saquinavir occurs in patients treated with saquinavir alone or in combination with RT inhibitors during phase 1111 clinical studies. Toward. this goal, we isolated HIV-1 proteinase genes from integrated proviral DNA of patients' peripheral blood mononuclear cells (PBMe) and determined individual sequences over the complete open reading frame.
Materials and Methods

DNA extraction and polymerase chain reaction (peR) amplifi-
cation ofthe HIV-I proteinase gene. PBMC (~1-2 X 10 6 ) were dissolved in 300 ILL of PCR lysis buffer (10 ruM TRIS-HCL, pH 8.5, 50 ruM KCI, 0.05% Tween 20, 5% NP-40) and digested at 56°C for 4 h in the presence of 100 ILg of proteinase K. The digest (5 ILL) was used directly in a 100-ILL PCR reaction (50 ruM KCI, 1.5 ruM MgCh, 10 ruM TRIS-HCI [pH 8.3, at 25°C],0.2 ruM each JID 1996; 173 (June) dNTP, and 0.001% gelatin) with 50 pmol of primers Sl729 (5'-GAAGGGCACATAGCCAGAAATTGCAGGG) and AS2217 (5'-TCTTCTGTCAATGGCCATTGTTTAAC) and 2.5 U of DNA polymerase (AmpliTaq; Perkin-Elmer, Norwalk, CT).
The reaction conditions were denaturation for 5 min at 95°C followed by addition of enzyme and three 20-s cycles of denaturation (95°C), annealing (55°C), and elongation (72°C). Subsequently, the annealing temperature was raised to 60°C, and the reaction was continued for 30 cycles. Five microliters from the first PCR were used as template for a second PCR with nested primers 1729 SpeI (5'('"ATGCACTAGTGAAGGGCACATAGC-CAGAAATTGCAGGG) and AS2l79 NotI (5'-TTAAGCGGC-CGCCATTCCTGGCTTTAATTTTACTGGTAC) with the following cycling conditions: denaturation (20 s, 95°C), annealing (20 s, 60°C), and elongation (20 s, 72°C) for 30 cycles. The amplicon was separated from primers and template by PCR kit (Qiaquick; Qiagen, Basel, Switzerland), and NotI/SpeI digested. After the digestedproduct was separated on low-meltagarose gel, molten gel slices were used for ligation into correspondingly digested and dephosphorylatedpBluescript II SK(-) vector (Stratagene, La Jolla, CA). Escherichia coli TG-l was transformed with ligated plasmid and plated onto selective media. Individual colonies were selected, and the proteinase insert was amplifiedby PCR from lysed bacteria and purified as described above. Alternatively, plasmid DNA was isolated and purified by a plasmid kit method (Qiaprep; Qiagen).
For sequencing, we used 200 ng of PCR product or 1.5 f-lg of plasmid DNA and a cycle sequencing kit (PRISM Ready Reaction Dye Deoxy Terminator [no. 401 628]; Applied Biosystems, Foster City, CA) with DNA polymerase (AmpliTaq; Perkin-Elmer). The conditions for 25 cycles were 93°C for 30 s, 45°C for 30 s, and 58°C for 240 s. The sequencing primer was 5' -GGCTTTAATTTT-ACTGGTAC. All reactions were analyzed on 6% polyacrylamide 8 M urea gel on a sequencer (model 373A; Applied Biosystems). The resulting DNA sequences were analyzed by computer with one of two software packages (GCG Sequence Analysis Package; Genetics Computer Group, Madison, WI, or GeneJockeyII; Biosoft, Cambridge, UK).
Determination ofvirus susceptibility to saquinavir and zidovudine. Methods were based on the protocol of the AIDS Clinical Trials Group (ACTG) Virology Committee Resistance Working Group [32] . HIV plasma isolates were previously titrated on phytohemagglutinin (PHA)-activated donor PBMC. Ten-fold dilutions of saquinavir (0.01-100 nM) were tested in triplicate on PHAactivated donor PBMC infected with 4000 TCID of the virus isolate. The IC 50 of the drug was calculated on the basis of p24 antigen production in the culture supernatants.
Determination ofHIV-l RNA in patient plasma. Viral plasma RNA concentrations were measured by a quantitative RNA-PCR protocol as described [33, 34] . The assays were done by Roche Biomedical Laboratories (Research Triangle Park, NC).
Results
Origin of Samples for Genotypic Analysis
For this study, we used material from saquinavir phase II II clinical studies V13330, V13329, 013328, and NV14255/ ACTG229. The design, objectives, and interim efficacy results have been or will be reported [14, 35] . Brief descriptions of the studies follow.
V13330. This study included subjects with advanced HIV-I infection (~300 CD4 cells/mrrr') who had not been treated previously with antiretrovirals. Patients were randomized to one of five treatment regimens to compare monotherapy with combination therapy: saquinavir alone (600 mg); saquinavir (75,200, or 600 mg) plus zidovudine (200 mg); or zidovudine (200 mg). All regimens were given 3 times a day. Material for genotypic analysis was obtained from patients receiving saquinavir monotherapy (600 mg) or saquinavir-zidovudine combination therapy (600 mg of saquinavir, 200 mg of zidovudine, 3 times/day).
V13329. Subjects had advanced HIV-I infection (~50 but 250 CD4 cells/rum") and had received zidovudine therapy.
Patients were randomized to one of three saquinavir monotherapy regimens (75, 200, or 600 mg, 3 times/day). Material for genotypic analysis was obtained from patients in the 600-mg regimen.
013328. Subjects had early HIV-I infection (~500 CD4 cells/mnr') and no prior antiretroviral treatment. They were randomized to one of four saquinavir monotherapy regimens (25, 75, 200 , or 600 mg, 3 times/day). Material for genotypic analysis was obtained from patients in the 600-mg regimen.
NV142551ACTG229. Subjects had advanced HIV-l infection (~50 but~300 CD4 cells/nun") and had received zidovudine for~16 weeks. Patients were randomized to one of three treatment regimens to compare double and triple combination therapy: zidovudine (200 mg) plus dideoxycytidine (ddC; 0.75 mg); saquinavir (600 mg) plus zidovudine (200 mg); or saquinavir (600 mg) plus zidovudine (200 mg) plus ddC (0.75 mg). All regimens were given 3 times a day. Material for genotypic analysis was obtained from patients receiving triple therapy.
Whenever possible, the genotypic analysis was done on HIV-1 proteinase genes amplified from patients' PBMC that had not been cultured in vitro. In a few cases in which material was not available, DNA from cocultured PBMC was used. Table 1 shows details of the material used for genotypic analysis (i.e., time points, number of patients, and sequences).
Saquinavir Resistance Mutations: Frequency and Kinetics
Selection for saquinavir resistance in cell culture has repeatedly resulted in virus variants with one or both of two exchanges in the proteinase gene: These have not been observed in wild type virus (i.e., G48V and L90M). In most cases, G48V was the first mutation to appear, and continued selection resulted in highly resistant doubly mutant virus [29] [30] [31] . Since the genetic basis for resistance in vivo was unknown at the onset of this study and thus the possibility for selection for further mutations existed, we decided to sequence the complete proteinase reading frame instead of using PCR to detect Val48 or Met90 mutations. However, extensive genotyping did not reveal other reproducible mutational changes at significant frequency in virus from patients after extended saquinavir treatment. Thus, a saquinavir-resistant genotype is defined here solely on the basis of the G48V and L90M mutations. In table 2, the overall frequencies of resistant virus for the four trials are summarized on a "per patient" basis. Where available, data are given for 2 saquinavir treatment time points: 4-6 and 7-12 months. Genotypic resistance is defined as the occurrence of mutations at positions 48 and 90 in any of the sequences analyzed from 1 patient at a given time point (i.e., if 1 of 10 sequences showed a resistance mutation, the patient was listed as resistant). This definition was chosen to compensate for any delay between the appearance of mutant virus in the PBMC compartment compared with plasma.
At the later time point, 45% of patients receiving saquinavir monotherapy or saquinavir-zidovudine combination treatment had resistant virus in the PBMC compartment. By study, percentages ofpatients with resistant virus at '"" 1 year of treatment were 013328, 12.5%; V13329, 50%; and V13330 mono-and combination therapy, respectively, 64% and 50%. In ACTG229, 22% of patients receiving triple therapy had resistant virus. Sequencing data from earlier time points for V13329 and ACTG229 showed 33% and 12% resistant virus, respectively. Table 3 provides a more detailed view of the genotypic analysis from trials V13329, V13330, and ACTG229 at different time points. The numbers of sequences available for comparison are given as are numbers of patients from whom material for genotyping was obtained. Genotypic resistance is listed separately for Va148, Met90, and double mutants.
L90M was clearly the predominant resistance mutation selected in vivo. About 18% of all proteinase sequences isolated at the later time point carried this mutation. G48V occurred significantly less often-2% of the time. Doubly mutant sequences are rarely observed in patient-derived provirus and were seen in <2% ofpatients in this sequence collection. L90M exchanges occurred in 7 of 38 patients and in 21 of 55 for the intermediate and late time points, respectively. For G48V, the corresponding numbers were 4 of 38 and 2 of 55. Whereas there was a marked increase over time in resistance mutations at position 90, the frequency of the G48V exchange stagnates or even decreases toward later time points. The same observation holds for the double mutant, the already low number at intermediate time (2/38) decreased toward the later time point (1/55). It may be noteworthy that in 1 patient a G48V exchange was observed at 16 weeks; this was no longer seen in the week 52 sequences in the absence of any further resistance mutations at position 90 (data not shown).
In the majority of the patients termed resistant in table 2, the proteinase sequences derived from virus in PBMC were a heterogeneous group of wild type and mutant genes. Frequently, there were <50% mutant sequences (data not shown). Thus, penetration of the mutant virus into the PBMC compartment is a slow process, and a major reservoir of wild type virus genomes exists even after long periods of treatment with the proteinase inhibitor.
A predominance of Met90 over Val48 was also observed in cases in which PBMC-derived provirus and plasma virus were analyzed in parallel and should thus reflect the virus population of both compartments (data not shown). Therefore, according to genotypic data, the provirus population after 1 year of saquinavir treatment acquired only a partial resistance to the inhibitor. The G48V mutant was highly underrepresented compared with in vitro selections.
Saquinavir Resistance and Virus Response to Treatment
It has been firmly established by in vitro selection and by targeted mutagenesis that G48V or L90M mutations (or both) (16) (17) (18) (19) (20) (21) (22) (23) (24) 103 (9) 10 (2) 21 (2) RNA responses were significantly different in those receiving saquinavir monotherapy (table 4) than in those receiving saquinavir-zidovudine combination therapy (table  5) . Of 11 patients receiving monotherapy, 6 did not respond and 5 responded transiently. There were no clear correlations between responses to treatment and saquinavir resistance. In the combination arm, 15 patients could be evaluated: 1 did not respond to treatment, 8 responded transiently, and 6 had NOTE. 600 mg of saquinavir was given 3 times/day. R, resistant; S, sensitive; NT, not tested.
* Patients 121 and 221 did not receive saquinavir for -6 weeks before samples for resistance analysis were obtained.
t -, decrease in viral plasma RNA was not > 1 log at any time during treatment (nonresponder); +, initial decrease in viral plasma RNA was> 1 log but increased to < 1 log before week 40 of treatment (transient responder).
in the viral proteinase decrease the drug susceptibility of virus; however, the extent of change in sensitivity may depend on the genetic background of the virus strain under selection and on residues in the proteinase polypeptide whose precise contributions are poorly understood. Thus, it was important to compare genotypic with phenotypic changes in drug sensitivity for virus isolated at matching time points to correlate in vivo mutations with an altered phenotype. Genotypic resistance was again defined as occurrence of mutations at positions 48 and 90 in any of the sequences analyzed from a patient at a.given time point. Phenotypic resistance was defined as a ;::10-fold decrease in drug susceptibility compared with baseline virus isolated from the same patient. We compared our results on viral genotype with changes in virus load to study whether resistance in vivo affects the treatment response. For this purpose, patients were divided into 3 groups according to changes in viral plasma RNA: nonresponders (-), in whom decreases in plasma RNA levels (copies of RNA/mL) never exceeded I log; transient responders (+), in whom the initial decrease in plasma RNA levels exceeded 1 log but increased~1 log before week 40; and sustained responders (+ +), who had a stable decrease of ;::1 log up to week 40.
Data from study V13330 late time points (>24 weeks) were evaluated and are shown in tables 4 and 5.
Of 21 patients from whom both genotypic and phenotypic data were available for comparison, 15 showed correspondence of geno-and phenotype when classified as resistant or sensitive according to the criteria described above. On 4 occasions, genotypic analysis indicated wild type virus while drug-susceptibility testing showed a decline in sensitivity of > lO-fold (table   4: patients 111 and 208; table 5 : patients 209 and 503). This discrepancy may reflect the faster turnover of plasma virus compared with provirus in the PBMC compartment [36, 37] . Twice we found genotypic resistance mutations in the absence of a resistant phenotype in the antiviral assay ( 
Downloaded from https://academic.oup.com/jid/article-abstract/173/6/1379/1010058 by guest on 09 April 2019 Table 6 summarizes a search of our proteinase sequence data base. Leu is the consensus residue at position 10; He occurred in -9% of baseline sequences, and its incidence doubled during the early treatment period. The Leu to Arg mutation did not occur in any of the sequences analyzed, although a Leu to Val exchange was noted infrequently. The high number of residues listed as "X" reflects mostly ambiguous sequence readings at this position due to our sequencing protocol, which used a sequencing primer C-terminal to the proteinase reading frame. ++, stable decrease of~I log up to week 40 (sustained response).
t Genotypic resistance defined as mutations at positions 48 (Gly48--+Val) or 90 (Leu-rlvlet) or both.
t Phenotypic resistance defined as~lO-fold increase in IC so vs. virus from same patient isolated before onset of treatment. Data in parentheses are increases in IC so .
sustained responses. Genotypic analysis of 5 patients in the latter group showed that 4 retained the wild type proteinase sequence after treatment for -1 year. However, only 2 of 8 patients who responded transiently still had a wild type genotype.
Genotypic Trends in HIV Proteinase during Saquinavir
Treatment
Although the causative role of the G48V and L90M exchanges in the development of saquinavir resistance was confirmed by the in vivo data described, a selection for additional exchanges in the proteinase polypeptide by prolonged saquinavir treatment could not be excluded. Thus, it was of interest to analyze our sequence data base for trends at other positions that would indicate additional variant genotypes. This question has gained additional importance since it was recently reported that patients treated with the structurally different HIV-1 proteinase inhibitor MK-639 select for virus variants with broad resistance to HIV proteinase inhibitors, including saquinavir [38] . Although the precise genetic basis for this cross-resistance remains elusive, certain mutations have been implicated by genotyping and directed mutagenesis as contributing to this (table 3) . Thus, saquinavir core mutations at positions 48 and 90 could not be detected in baseline virus but increased during treatment.
To evaluate residues at positions 10, 36, 46, 63, 71, 82, and 84 in relation to position 90, we analyzed our sequence data from the late time point (r-week 40, table 6) for combinations of Leu90 or Met90 with the predominant residues at these positions (table 7) . IlelO or Ile36 are minor populations in combination with Leu90 but become the major species in combination with a Met90. Leu46 occurs rarely, but its frequency is significantly higher in the Met90 sequence population than in the Leu90 group. There were also positive correlations of Pro63 or Thr71 with Met90. Positive correlations with Met90 were not observed for position 82, but there was a significant association ofVal84 with Met90. However, Val84 remained a minor genotype in this population, and all sequences were derived from 1 patient (table 6). Together, these correlation studies indicate that the Met90 mutations accumulate preferentially in proteinase genes that carry certain nonconsensus residues at positions 10, 36, 63, and 71.
Discussion
We analyzed the development of HIV resistance to saquinavir after prolonged treatment. Saquinavir was given as proteinase inhibitor monotherapy or in combination with RT inhibitors. Results of the genotypic analysis showed that the frequency of resistance to saquinavir monotherapy or saquinavir-zidovudine combination therapy is comparable to that of zidovudine monotherapy (i.e., after 1 year of treatment, -50% of treated patients carry virus with mutations specifying resistance). The frequency appeared to be markedly lower in samples from the triple therapy arm of ACTG229 at week 48. The reasons for the lower incidence in that trial are not known but may relate to enhanced suppression of virus turnover. Saquinavir resistance in HIV-1 with zidovudine-resistant RT has been reported, and the 3 patients in ACTG229 who had L90M mutant virus at week 24 also had RT genes with zidovudineresistant mutations (e.g., codon 215; data not shown). Thus, zidovudine and saquinavir resistance apparently are not mutually exclusive, in agreement with their localization to different genes. Corresponding data for saquinavir and ddC mutations are not yet available. Genotype analysis of samples from the saquinavir-ddC combination arm of this study will help to clarify this question.
We do not know the extent to which the frequency of saquinavir resistance mutations compares with other proteinase inhibitors, since only limited data from clinical trials with such inhibitors have been published. Condra et al. [38] recently described 4 patients treated with inhibitor MK-639; all showed some decrease in sensitivity at week 24 of therapy [38] . This suggests a higher incidence than observed for saquinavir, although it is not clear if these 4 patients were randomly selected and are thus representative of a larger group of patients. When genotypic resistance to saquinavir is grouped by underlying mutation, an interesting discrepancy between in vivo and in vitro selected virus becomes obvious. Whereas in vitro selection seems to favor the G48V exchange as the first step toward resistance, and continued selection yielded doubly mutant virus (Va148 + Met90 [29, 30] ), in most cases in vivoselected virus exclusively carries the L90M exchange. In I patient, we noted a G48V mutant proteinase at week 24 but not at week 48, despite continued saquinavir treatment and the absence of a resistance mutation at position 90 that could compensate for the loss of Va148. Furthermore, there was a clear increase in Met90 mutants between weeks 24 and 48, whereas the number of Val48 mutant virus decreased with continued treatment. In vitro observations on G48V singlemutant virus have not suggested any major effect of this mutation on viability, while a decrease in drug susceptibility has been clearly shown [30] .
The same arguments hold for the doubly mutant virus. Although these in vitro observations do not necessarily exclude a significant loss of fitness under in vivo conditions, other factors could conceivably contribute to the underrepresentation of this variant in patient-derived samples (e.g., it would be of interest to study whether an immunologic selection limits the growth of such virus in patients, possibly via recognition of a new potent epitope formed by the protease with a Val48 residue). Low drug exposure at sites of active replication could conceivably favor single-mutant over doubly mutant virus; however, it is not obvious why it should favor L90M over G48V or why the latter genotype decreases after week 24.
Our in vivo results largely confirmed the assumption, based on in vitro results, that G48V and L90M are the core mutations leading to decreased susceptibility to saquinavir. When results of the genotypic analysis were compared with drug susceptibility testing by standard virus assay, a large degree of correspondence was seen. In 15 of 21 matched samples, resistance mutations in proteinase were accompanied by a~IO-fold decrease in drug sensitivity from baseline. A delayed turnover of PBMC virus relative to plasma virus has been reported repeatedly in patients treated with RT or proteinase inhibitors, as shown by the different kinetics of mutant virus in these compartments [36, 37] . A similar cause probably accounts for the 5 saquinavir-treated patients in whom a resistant phenotype was not matched by a corresponding genotype. Since genotyping was done on PBMC virus and drug sensitivity was tested on plasma virus, recent selection for resistant virus may not have been detected by the genotypic analysis. Thus, our method for assessing resistance may underestimate the actual proportion at early time points but should later approach the level shown in biologic assays. Indeed, in some cases in which we assayed plasma and PBMC samples from the same time point, we observed resistance mutations in plasma virus that were absent in PBMC virus or a homogenous mutant population in the plasma while PBMC virus was still a mixture of wild type and mutant virus (data not shown).
In 2 cases, genotyping indicated the presence of resistant virus, while phenotypic analysis showed normal sensitivity. In both sets of sequences, Met90 mutants were a minor genotype (1 of 11 for patient 221 and 1 of 10 for patient 226) and may indicate an early state of selection for resistance. Since no genotypic analysis was done on virus grown from plasma samples, it remains possible that wild type virus was expanded preferentially from the plasma samples and subsequently tested in the antivirus assay.
An inverse relation between resistance and response to therapy in terms of extent and durability of the decrease in plasma viral RNA load was suggested by the data from the V13330 combination treatment arm. The patients who experienced a sustained decrease in viral RNA were largely free of resistant virus by both phenotypic and genotypic analysis. In contrast, patients who responded transiently carried mostly resistant virus at the later time point. Resistance to zidovudine was only rarely observed in this group and was significantly less than in the zidovudine monotherapy arm (unpublished data). A causative relation between rebounding plasma RNA levels and the emergence of resistant virus was recently suggested by studies on the dynamics of HIV-1 infection, although other factors may contribute to this rebound, as suggested by studies with zidovudine [36] [37] [38] [39] . A causative relation between the presence of saquinavir-resistant virus and an increase in plasma RNA load would be in line with the dose-dependent decrease in RNA during saquinavir monotherapy (unpublished data), indicating that exposure of virus to drug directly determines the strength of its antiviral activity.
Resistance mutations may affect susceptibility to more than one drug when they bind to the same site of their target protein.
A case in point is the nonnucleoside RT inhibitors in which a YI81C exchange decreases virus sensitivity to several drugs of this group [40] . Proteinase inhibitors may likewise select for genotypes with altered affinity to drugs. Some positions in the proteinase polypeptide may be critical in this regard, especially those that are localized to the flap (residues 48, 50) or the substrate PlIPI' binding sites (residues 82, 84). Val48 can arise after treatment with inhibitor A77003 or SC52121 [41, 42] and cross-resistance of saquinavir-resistant virus with inhibitor AG1543 has been observed (unpublished data). Broad cross-resistance to six proteinase inhibitors, including saquinavir, was reported recently for virus isolated from patients 6 months after treatment with inhibitor MK-639, and residues Arg l O, Ile46, Pro63, Thr82, and Val84 have been invoked in this phenomenon [38] . In I of those patients, virus with an L90M exchange was observed, but decreased susceptibility to saquinavir was also reported for virus isolates lacking Val48 and Met90.
Analysis of our sequence data base from all phase 1111 studies has failed to detect mutations with potential for cross-resistance at positions 10 and 82.· Only minor incidences were seen at positions 46 and 84, revealing Pro63 as a major genotype in wild type virus. Our data indicate, however, that Met90 muta-tions accumulate with a higher frequency in the proteinase genes that carry minor, nonconsensus residues at positions 10, 36, 63, and 71 (IlelD, Ile36, Pro63, Thr71). These 4 positions represent natural polymorphic sites in the proteinase gene. We previously reported a similar finding for in vitro selection for saquinavir resistance [40] . In that study we noted a mixed wild type population at the onset of selection (Met/Ile36, Lys/Arg57, Leu/Val63) that resolved into a homogeneous population early in the selection (before the occurrence of Val48 or Met90). Whether any of these nonconsensus residues at positions 10, 36, 63, and 71 alone or in combination decrease susceptibility to saquinavir or whether they balance any negative effect of the Met90 mutation on virus fitness is unclear. Both Ile46 and Val84 are positively correlated with Met90 but remain minor populations in the PBMC compartment. It will be of interest to extend this correlation analysis to include more residues and to study baseline sequences for subspecies that may have an increased potential for resistance development.
Evidence from biologic assays is needed to assess the relevance of these combined exchanges for the susceptibility of the resultant virus to other proteinase inhibitors. It will also be important to determine if these observations hold for later therapy time points and for exposure to higher doses of inhibitor. Currently, treatment with saquinavir does not seem to exclude later treatment with other proteinase inhibitors, and combining saquinavir with other inhibitors of this enzyme may be a valid therapeutic approach.
